Holen Sie sich die Stockscreener-App
422.22
0.46%
-1.4224
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$423.64
Offen:
$424.01
24-Stunden-Volumen:
213.21K
Relative Volume:
0.08
Marktkapitalisierung:
$228.32B
Einnahmen:
$37.30B
Nettoeinkommen (Verlust:
$7.80B
KGV:
29.36
EPS:
14.3793
Netto-Cashflow:
$8.60B
1W Leistung:
+3.85%
1M Leistung:
-2.48%
6M Leistung:
+20.83%
1J Leistung:
+49.44%
1-Tages-Spanne:
$421.19
$426.59
1-Wochen-Bereich:
$403.88
$426.59
52-Wochen-Spanne:
$283.00
$447.03
Amgen Inc Stock (AMGN) Company Profile
Firmenname
Amgen Inc
Sektor
Telefon
(805)447-1000
Adresse
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
422.32 | 224.15B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,186.61 | 1.05T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
267.64 | 653.61B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
263.26 | 467.12B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
147.50 | 367.07B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
144.56 | 276.48B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-21 | Eingeleitet | Canaccord Genuity | Hold |
| 2026-03-10 | Eingeleitet | Jefferies | Hold |
| 2026-02-20 | Eingeleitet | Barclays | Equal Weight |
| 2026-01-20 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Fortgesetzt | UBS | Buy |
| 2025-12-05 | Hochstufung | Erste Group | Hold → Buy |
| 2025-11-24 | Fortgesetzt | Truist | Hold |
| 2025-11-13 | Eingeleitet | Scotiabank | Sector Outperform |
| 2025-09-03 | Fortgesetzt | Raymond James | Mkt Perform |
| 2025-05-20 | Fortgesetzt | Guggenheim | Neutral |
| 2025-04-22 | Fortgesetzt | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Fortgesetzt | BofA Securities | Underperform |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-11-14 | Eingeleitet | Citigroup | Neutral |
| 2024-10-17 | Eingeleitet | Bernstein | Outperform |
| 2024-10-14 | Herabstufung | Truist | Buy → Hold |
| 2024-09-27 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Hochstufung | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Hochstufung | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Fortgesetzt | Raymond James | Mkt Perform |
| 2024-02-07 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Hochstufung | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Hochstufung | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Eingeleitet | Deutsche Bank | Hold |
| 2023-11-02 | Hochstufung | Truist | Hold → Buy |
| 2023-10-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-10-17 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Fortgesetzt | BofA Securities | Neutral |
| 2023-09-06 | Eingeleitet | HSBC Securities | Buy |
| 2023-04-24 | Bestätigt | Oppenheimer | Outperform |
| 2023-03-13 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Bestätigt | Truist | Buy |
| 2022-11-18 | Eingeleitet | Credit Suisse | Underperform |
| 2022-10-31 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2022-02-09 | Bestätigt | Barclays | Equal Weight |
| 2022-02-09 | Bestätigt | Jefferies | Buy |
| 2022-02-09 | Bestätigt | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Bestätigt | Oppenheimer | Outperform |
| 2022-02-09 | Bestätigt | Wells Fargo | Equal Weight |
| 2022-01-05 | Herabstufung | BofA Securities | Buy → Neutral |
| 2021-12-09 | Fortgesetzt | Wells Fargo | Equal Weight |
| 2021-12-06 | Eingeleitet | Goldman | Buy |
| 2021-11-19 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2021-09-23 | Herabstufung | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Eingeleitet | Daiwa Securities | Buy |
| 2020-10-28 | Eingeleitet | UBS | Neutral |
| 2020-10-26 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Hochstufung | Truist | Hold → Buy |
| 2020-10-09 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Herabstufung | Truist | Buy → Hold |
| 2020-10-08 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Fortgesetzt | Guggenheim | Neutral |
| 2020-03-31 | Eingeleitet | Wolfe Research | Peer Perform |
| 2020-03-30 | Hochstufung | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Hochstufung | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Eingeleitet | Barclays | Equal Weight |
| 2020-01-31 | Herabstufung | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Eingeleitet | Raymond James | Mkt Perform |
| 2019-12-17 | Fortgesetzt | Morgan Stanley | Overweight |
| 2019-11-12 | Eingeleitet | SunTrust | Buy |
| 2019-11-05 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Fortgesetzt | BofA/Merrill | Neutral |
| 2019-08-19 | Herabstufung | Mizuho | Buy → Neutral |
| 2019-05-23 | Hochstufung | Citigroup | Neutral → Buy |
Alle ansehen
Amgen Inc Aktie (AMGN) Neueste Nachrichten
Why Amgen’s Pipeline Just Got More Interesting - Yahoo Finance
Amgen (AMGN) Sells its Deerfield Campus for $151 Million and Leases it Back - Yahoo Finance
Amgen Inc Agencies, 2011 - OpenSecrets
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’ - stocktwits.com
How Phase 3 Sjögren’s Results At Amgen (AMGN) Has Changed Its Investment Story - simplywall.st
Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal - Yahoo Finance
Yaron Werber: Celldex's Urticaria Drug Won't Carry a Black Box; Amgen Maps a $25 Billion Sjogren's Market - finance.biggo.com
Amgen (AMGN) Rises Higher Than Market: Key Facts - Yahoo Finance
Obesity Drug Sector Evolves as Amgen (AMGN) Advances Pipeline Am - GuruFocus
Mesirow buys Amgen’s Deerfield campus in $151 million sale-leaseback - Crain's Chicago Business
Amgen stock last at USD 410.86, up 1.19 percent in New York trading - AD HOC NEWS
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know - Yahoo Finance
Amgen stock trades at USD 406.04 after pipeline win - AD HOC NEWS
Amgen Inc. $AMGN Stock Purchased by Envestnet Portfolio Solutions Inc. - MarketBeat
Amgen stock heads into the open after a 0.01 percent loss - ad-hoc-news.de
Amgen Inc. (AMGN34.SA) Stock Price, News, Quote & History - Yahoo! Finance Canada
Amgen Gains as Sjögren's Drug Clears Phase 3 - GuruFocus
Global Autoimmune Disease Therapeutics Market is Predicted to Cross USD 60 Billion by 2034 | DelveInsight - GlobeNewswire Inc.
Amgen (AMGN) Stock Could Be 40% Undervalued On Phase 3 Sjögren’s Data - simplywall.st
Amgen reports positive topline Phase 3 Sjögren’s results - European Pharmaceutical Review
Amgen stock heads into the open after a 4.34 percent gain - AD HOC NEWS
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks - The Globe and Mail
Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease - Yahoo! Finance Canada
QRG Capital Management Inc. Increases Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Envestnet Asset Management Inc. Acquires 326,260 Shares of Amgen Inc. $AMGN - MarketBeat
When Colorectal Cancer Strikes Early - Amgen
Amgen stock was last quoted after the close - AD HOC NEWS
Amgen price target raised by Jefferies to $410 after positive Sjögren's data - Yahoo Finance
Amgen says dazodalibep met Phase 3 Sjögren's endpoint - Mugglehead Investment Magazine
Amgen Stock Forecast: AMGN Reclaims $410 as Pipeline Catalysts Build - TradingKey
AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study - Yahoo Finance
Jefferies Adjusts Amgen Price Target to $410 From $367, Maintains Hold Rating - marketscreener.com
Amgen Stock Gains After Announcing Positive Phase 3 Sjögren’s Disease Trial Results - TIKR.com
Canaccord reiterates Amgen stock Hold rating on pipeline win By Investing.com - Investing.com Canada
Amgen stock rises 4.34 percent as trial data lift pipeline hopes - AD HOC NEWS
Oppenheimer reiterates Amgen stock rating on positive trial data - Investing.com India
Jefferies raises Amgen stock price target on drug trial success - Investing.com India
Amgen (AMGN) Following Its Sjögren's Trial Win Through A Valuation Lens - simplywall.st
Amgen touts Phase III success in systemic Sjögren's disease - The Pharma Letter
What is changing in the investment case for Amgen (NASDAQ:AMGN)? - Kalkine Media
Ionis, Otsuka's Phase 3 win in ALS subtype; Boehringer's up to $1B cancer deal - Endpoints News
Amgen Inc. (NASDAQ:AMGN) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Is Amgen Inc (AMGN) Overvalued After 4.3% Rally? GF Value Says O - GuruFocus
Amgen's autoimmune drug succeeds in late-stage trial - Reuters
Amgen stock surges on positive Sjögren’s trial results - Investing.com
Amgen Inc.’s Stock Price Soars to $410.24, Marking a Robust 4.34% Increase - Smartkarma
Amgen stock ends the day 3.36 percent higher at USD 406.37 - AD HOC NEWS
Amgen’s Dazodalibep Outlook Is Brighter After First Phase III Readout - insights.citeline.com
Amgen, Vicor among market cap stock movers on Tuesday - Investing.com India
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
Amgen Drug Meets Goals of Key Test in Common Autoimmune Disease With No Approved Meds - MedCity News
Finanzdaten der Amgen Inc-Aktie (AMGN)
Umsatz
Nettogewinn
Free Cashflow
ENV
Amgen Inc-Aktie (AMGN) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Khosla Rachna | SVP, Business Development |
Aug 11 '26 |
Sale |
412.57 |
2,000 |
825,134 |
6,404 |
| Khosla Rachna | SVP, Business Development |
Aug 13 '26 |
Sale |
416.43 |
1,252 |
521,365 |
6,404 |
0.52%
0.13%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):